Subject: RE: request from MoH Georgia
From: GileadClinicalTrials <[email-masked]>
To: "[email-masked]" <[email-masked]>
Date: Fri, 03 Apr 2020 07:40:30 +0000

Dear Mrs. Nikoleishvili,

Thank you for your inquiry regarding potential participation in our COVID-19 clinical trials. At this point of time, Gilead has reached its capacity and cannot add any new sites to the ongoing studies (NCT04292899 [EudraCT 2020-000841-15)
and NCT04292730 [EudraCT 2020-000842-32). Information

regarding Clinical Trials Gilead Sciences is currently conducting and that may actively be recruiting are published in Clinical Trial Registries such as ClinicalTrials.gov (www.clinicaltrials.gov)
and EU-CTR (https://www.clinicaltrialsregister.eu/ctr-search/search).

Kind Regards,

Gilead Sciences Clinical Trials

| Clinical Trials |  Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA  94404
|

From: Maia Nikoleishvili <[email-masked]>

Sent: Tuesday, March 17, 2020 10:35 AM

To: Coronavirus response <[email-masked]>

Cc: Tamar Gabunia <[email-masked]>

Subject: [EXTERNAL] request from MoH Georgia

Importance: High

Dear Sir/Madam,

I would like to kindly address you from the Ministry of IDPs from the Occupied Territories, Labour, Health and Social Affairs of Georgia. Please, find the enclosed letter signed
by the Minister – Ms. Ekaterine Tikaradze regarding the possibility of engagement in the study of Remdesivir for the treatment of the patients with severe acute respiratory syndrome of COVID-19.

We kindly ask you to assist us in obtaining the response as soon as possible to the request addressed to Dr. Daniel O'Day.

Thank you in advance for continued support and partnership.

Looking forward to hearing from you.

With best regards,

Maia Nikoleishvili MPA

Acting Head of International Relations and Protocol Division of Administration

Ministry of IDPs from the Occupied Territories, Labour, Health and Social Affairs of Georgia

Address: 144 Tsereteli ave., 0159 Tbilisi, Georgia

Tel.: +995 32 2510034 (0803)

Cell phone: +995 577272713

E-mail:
[email-masked]